Aurinia (NASDAQ: AUPH) officer to sell 47,000 shares for taxes

Aurinia Pharmaceuticals (AUPH) officer Stephen P. Robertson plans to sell 47,000 shares under Rule 144 to cover tax obligations from vesting performance stock units, with the sale expected to occur on or after 08/21/2026. The transaction will be executed through Morgan Stanley Smith Barney LLC on NASDAQ.

Original reporting
Published Aug 22, 2026, 1:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 6:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AUPH
Bearish
medium confidence
Mentioned
$AUPH
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$AUPHBearishLow
01

Why it matters

The filing adds new supply information for AUPH, which could affect short-term price dynamics.

02

Market read

First public notice of an insider's planned share sale for AUPH, providing fresh data for traders monitoring insider activity.

03

What to watch

If the performance stock units vest at a high price, the sale could reflect confidence in the company's valuation.

Relevance 4/10Novelty 4/10Timing: sale scheduled for 08/21/2026 (today)

Background

Form 144 filings disclose planned sales of restricted securities under Rule 144, often used by insiders to meet tax obligations.

Company-level read

Ticker impact

$AUPHBearishMedium confidence
Context

Officer Stephen P. Robertson filed a Form 144 indicating intent to sell up to 47,000 AUPH shares on 08/21/2026 to cover tax withholding.

Expected impact

Small short-term dip expected as shares become available.

Evidence & confidence

The sale size is modest relative to float, but insider sales often signal limited confidence and add supply.

Market effects

Minimal impact on the broader biotech sector.

No significant regional effect.

Limited to investors tracking AUPH insider activity.

Counterpoint

The insider sale may be routine tax planning and not indicative of negative outlook.

Key entities

  • Stephen P. Robertson

    Aurinia officer filing the Rule 144 notice.

  • Morgan Stanley Smith Barney LLC

    Designated broker for the planned share sale.

Related articles

$AUPHMedAI 8/10

Aurinia Skids on Results

Aurinia Pharmaceuticals reported Q3 and YTD 2026 revenue of $83.7M and $244.6M, up 14% and 19% YoY. LUPKYNIS sales rose 12% and 18% YoY for the same periods. License, collaboration, and royalty revenue increased 54% and 39% YoY. Net income before taxes grew 21% and 67% YoY.

$AUPHHigh

Aurinia Pharmaceuticals stock falls 3% on Q3 miss, soft guidance

Aurinia Pharmaceuticals (AUPH) reported Q3 earnings of $0.23 per share, missing estimates by $0.01, and revenue of $83.7M, slightly below expectations. Shares fell 3.43% premarket. The company raised 2026 revenue guidance to $325M-$330M, below analyst consensus. LUPKYNIS sales grew 12% YoY to $79.4M. The company also initiated a Phase 4 study for lupus nephritis treatments.

$AUPHHigh

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (AUPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress EDMONTON, Alberta – October 30, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial resul